Hyphens Pharma International Limited (SGX:1J5)

Singapore flag Singapore · Delayed Price · Currency is SGD
0.3250
+0.0050 (1.56%)
At close: Aug 26, 2025
1.56%
Market Cap101.93M
Revenue (ttm)185.32M
Net Income (ttm)6.46M
Shares Out308.87M
EPS (ttm)0.02
PE Ratio16.13
Forward PE9.14
Dividend0.02 (4.62%)
Ex-Dividend DateMay 7, 2025
Volume207,700
Average Volume202,030
Open0.3300
Previous Close0.3200
Day's Range0.3250 - 0.3300
52-Week Range0.2600 - 0.3450
Beta-0.10
RSI56.56
Earnings DateAug 14, 2025

About SGXC:1J5

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Specialty pharma principals; Proprietary brands; and Medical hypermart and digital segments. The Specialty Pharma Principals segment markets and sells specialty pharmaceutical products, including contrast media products, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products through... [Read more]

Industry Pharmaceutical Preparations
Founded 1998
Employees 474
Stock Exchange Singapore Exchange - Catalist
Ticker Symbol 1J5
Full Company Profile

Financial Performance

In 2024, SGXC:1J5's revenue was 195.42 million, an increase of 14.55% compared to the previous year's 170.60 million. Earnings were 10.19 million, an increase of 18.98%.

Financial Statements

News

There is no news available yet.